论文部分内容阅读
肿瘤浸润淋巴细胞(TILs)可以提高子宫内膜癌、结肠癌、恶性黑色素瘤等多种癌症患者的生存率。为了评估TILs与非小细胞肺癌(NSCLC)预后的相关性,Horne ZD等对273例行肺段或肺叶切除的ⅠA期NSCLC患者的5年生存率和5年无复发生存率进行了分析。结果显示:TILs+组和TILs-组患者的5年生存率比较差异无统计学意义(65%比60%,P=0.469),但TILs+组患者的5年无复发生存率较高(87%比73%,P=0.011),且在女性患者中尤为显著(P=0.016)。此外作者还发现,在
Tumor infiltrating lymphocytes (TILs) can improve the survival rate of many cancer patients, such as endometrial cancer, colon cancer and malignant melanoma. To assess the association between TILs and the prognosis of non-small cell lung cancer (NSCLC), Horne ZD et al. Analyzed the 5-year and 5-year, non-recurrence-free survival of 273 patients with stage A NSALC who underwent segmental or lobectomy. The results showed that there was no significant difference in 5-year survival between TILs + group and TILs- group (65% vs 60%, P = 0.469), but the 5-year recurrence-free survival rate was higher in TILs + group (87% vs 73%, P = 0.011), and was especially pronounced in female patients (P = 0.016). In addition the author also found that